Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

0
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Category

Show more Refine

For: Bellmunt J, Esteban E, Del Muro XG, Sepúlveda JM, Maroto P, Gallardo E, Del Alba AG, Etxaniz O, Guix M, Larriba JLG, Arranz JA, Redrado M, Calvo A. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. Eur Urol Oncol 2019;4:502-505. [PMID: 31477526 DOI: 10.1016/j.euo.2019.07.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Accepted: 07/19/2019] [Indexed: 12/21/2022]

For:	Bellmunt J, Esteban E, Del Muro XG, Sepúlveda JM, Maroto P, Gallardo E, Del Alba AG, Etxaniz O, Guix M, Larriba JLG, Arranz JA, Redrado M, Calvo A. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. Eur Urol Oncol 2019;4:502-505. [PMID: 31477526 DOI: 10.1016/j.euo.2019.07.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Accepted: 07/19/2019] [Indexed: 12/21/2022]

No articles found.

(The first 100,000 artilces are displayed in RCA.)